NCT06985615View on ClinicalTrials.gov

A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

January 14, 2026

Study Completion Date

May 14, 2026

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

Single dose of HDM1002 on Day 1

Single dose of HDM1002 will be administered on Day 1

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY